Response

Is CD103 a good surface marker for in vivo-activated effector/memory Treg cells in patients with chronic inflammation? Unknown yet
We observed that the percentage of CD103 ϩ cells among CD4 ϩ FoxP3 ϩ regulatory T (Treg) cells of donor DBA/2 mice was less than 10% before transplantation, and the percentage of CD103 ϩ cells among donor-type CD4 ϩ Foxp3 ϩ Treg cells increased to more than 55% in BALB/c recipients with chronic graft-versus-host disease (GVHD) and 70% in recipients without chronic GVHD after hematopoietic cell transplantation (HCT). 1 We also observed that the percentage of CD103 ϩ cells among 2 It has been well documented that the percentage of CD103 ϩ cells among Foxp3 ϩ CD4 ϩ Treg cells in healthy humans is low, around 5%. [3] [4] [5] However, it is still unknown whether Fopx3 ϩ Treg cells in human HCT recipients express CD103. It has been shown that the percentage of CD103 ϩ cells among CD25 hi CD4 ϩ T cells was significantly higher than that among CD25 Ϫ CD4 ϩ T cells in patients with multiple sclerosis. 6 In addition, in vitro TGF-␤-induced Treg cells were all CD103 ϩ . 7 TGF-␤ secretion is usually up-regulated in patients with chronic inflammation. 8 Therefore, although most of the Foxp3 ϩ Treg cells in normal humans do not express CD103, we cannot exclude the possibility that Foxp3 ϩ Treg cells in patients with chronic inflammation (such as chronic GVHD) will up-regulate CD103 expression. Because it has been reported that effector/memory Foxp3 ϩ Treg cells express CCR6 in mice 9 and they express CD39 in multiple sclerosis patients, 10 comparison of expression of CD103, CCR6, and CD39 by Foxp3 ϩ Treg cells in patients with chronic inflammation is required to find out which one is best for identifying the Foxp3 Treg cells.
